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Abstract: Sporotrichosis is a subcutaneous mycosis caused by Sporothrix schenckii complex. The disease
has been reported worldwide. However, the incidence of the etiological agent varies in its geographic
distribution. We studied 39 clinical isolates of Sporothrix schenckii from diverse regions in Mexico,
collected from 1998 to 2016. Molecular identification was performed by sequence analysis of the partial
calmodulin gene. In vitro antifungal susceptibility to amphotericin B (AMB), itraconazole (ITC),
voriconazole (VRC), posaconazole (PSC), fluconazole (FLC), terbinafine (TRB), caspofungin (CSF),
anidulafungin (ANF), and micafungin (MCF) was evaluated. Thirty-eight isolates of S. schenckii
complex were divided into five supported clades in a phylogenetic tree. The predominant clinical form
was lymphocutaneous (92.3%), fixed cutaneous (5.1%), and disseminated (2.5%). Terbinafine exhibited
the best in vitro antifungal activity, while fluconazole was ineffective against Sporothrix schenckii
complex. Our results showed diverse geographic distribution of clinical isolates in eight states;
definitive identification was done by CAL gen PCR-sequencing. In Mexico, S. schenckii is considered
to be an etiological agent of human sporotrichosis cases, and lymphocutaneous is the most prevalent
form of the disease. This study revealed four clades of S. schenckii sensu stricto by phylogenetic
analysis. Furthermore, we report one case of S. globosa isolated from human origin from the North
of Mexico.
Keywords: Sporothrix schenckii; Sporothrix globosa; CAL gen; clinical; origin; Mexico
1. Introduction
Human sporotrichosis is a subcutaneous mycosis caused by dimorphic fungi Sporothrix schenckii
species complex, which comprises four species of clinical importance: S. brasiliensis, S. globose, S. luriei,
and S. schenckii sensu stricto [1]. Sporotrichosis has been reported to be endemic in areas of Latin
America, South Africa, India, and Japan. In Latin America, the endemic areas are restricted to Peru,
Brazil, Mexico, Uruguay, Costa Rica, Guatemala, Colombia, and Venezuela. Sporotrichosis has emerged
as a major fungal infection over the last two decades due to changes in epidemiology distribution,
taxonomic evolution, and multiple outbreaks. Sporotrichosis in Mexico occurs primarily in regions
with a tropical and humid climate. While cases have been reported throughout the country, the highest
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prevalence has been noted in two zones: the states of Jalisco and Puebla [2]. Sporothrix species differ
in their geographical distribution. In this sense, S. brasiliensis is an emerging species restricted to
Brazil, and it is highly pathogenic to humans and animals [3]. S. globosa is distributed worldwide,
including Europe, the United States, South America, and Asia [2]. A study of clinical isolates from
Northeast China described two clades for S. globosa—subclade I and subclade II—and found they were
not related to geography [4]. In another study from Japan, S. globosa was divided into two subclades and
S. schenkii sensu stricto strains into three subclades [5]. Sporothrix luriei has been reported in three human
infections in Africa, Italy, and India [2]. Y. Zhang et al. showed five supported subgroups of S. schenckii
by CAL gen, which was also recognizable in AFLP data [6]. Molecular and phylogenetic analyses of
S. schenckii complex revealed some genetic diversity [7,8]. These species have distinct virulence profiles,
and they are rarely identified from clinical origins [5]. The different clinical forms are associated
with different species [4]. Sporotrichosis, restricted to skin, is treated by systemic chemotherapy with
potassium iodide. Other drugs commonly used are itraconazole for lymphocutaneous infections
and amphotericin B for disseminated cutaneous recurrent, extracutaneous, and lymphocutaneous
infection [5,8]. The variability in therapeutic efficacy and in vitro activity demonstrated in different
studies is attributed to the fact that S. schenckii is a complex of different species [9–11]. Herein,
we present Mexican clinical isolates identified by phenotypic characterization and partial sequences of
the CAL gen. The demographic characteristics of all stains from diverse regions in Mexico is shown.
The antifungal susceptibility patterns of these isolates were also determined in this study.
2. Materials and Methods
Thirty-nine clinical isolates were collected between 1998 and 2016 from different Mexican regions
(Table 1). All isolates were obtained from a collection of the Microbiology Department of the School
of Medicine, Universidad Autónoma de Nuevo León. The isolates were previously identified as
S. schenckii by morphology as well as macroscopic and microscopic features. All isolates had the data
regarding the origin of patients and type of lesion.
Table 1. Data of clinical human sporotrichosis and molecular analysis used in this study.
Strain Species (MolecularIdentification) Lesion Type Origin from Mexico
GenBank Accession
No. CAL Gen
Variant in
Phylogenetic Tree
98-164 Sporothrix schenckii Lymphocutaneous Mexico City MF948670 1
98-578 Sporothrix schenckii Lymphocutaneous Mexico City MF948671 1
99-098 Sporothrix schenckii Lymphocutaneous Mexico City MF948672 2
99-689 Sporothrix schenckii Fixed cutaneous Mexico City MF948673 1
00-45 Sporothrix schenckii Lymphocutaneous Mexico City MF948674 2
02-845 Sporothrix schenckii Lymphocutaneous Mexico City MF948675 4
02-846 Sporothrix schenckii Lymphocutaneous Mexico City MF948676 2
02-847 Sporothrix schenckii Lymphocutaneous Mexico City MF948677 2
02-849 Sporothrix schenckii Fixed cutaneous Mexico City MF948678 2
02-850 Sporothrix schenckii Lymphocutaneous Mexico City MF948679 1
02-851 Sporothrix schenckii Lymphocutaneous Mexico City MF948680 1
02-852 Sporothrix schenckii Lymphocutaneous Mexico City MF948681 2
03-017 Sporothrix schenckii Lymphocutaneous Veracruz MF948682 1
03-018 Sporothrix schenckii Lymphocutaneous Veracruz MF948683 1
06-345 Sporothrix schenckii Lymphocutaneous San Luis Potosi MF948684 2
06-743 Sporothrix schenckii Lymphocutaneous San Luis Potosi MF948685 4
07-089 Sporothrix schenckii Lymphocutaneous Coahuila MF948686 2
07-956 Sporothrix schenckii Lymphocutaneous San Luis Potosi MF948687 3
08-345 Sporothrix schenckii Lymphocutaneous Coahuila MF948688 2
08-390 Sporothrix schenckii Lymphocutaneous Mexico City MF948689 1
08-624 Sporothrix schenckii Lymphocutaneous Nuevo Leon MF948690 3
09-321 Sporothrix schenckii Lymphocutaneous Mexico City MF948691 3
11-131 Sporothrix schenckii Lymphocutaneous Puebla MF948692 1
11-567 Sporothrix schenckii Lymphocutaneous Nuevo Leon MF948693 1
12-078 Sporothrix schenckii Lymphocutaneous Oaxaca MF948694 1
13-670 Sporothrix globosa Lymphocutaneous Nuevo Leon MF948695 5
14-821 Sporothrix schenckii Lymphocutaneous Puebla MF948696 2
14-822 Sporothrix schenckii Lymphocutaneous Puebla MF948697 1
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Table 1. Cont.
Strain Species (MolecularIdentification) Lesion Type Origin from Mexico
GenBank Accession
No. CAL Gen
Variant in
Phylogenetic Tree
14-823 Sporothrix schenckii Lymphocutaneous Puebla MF948698 1
14-824 Sporothrix schenckii Lymphocutaneous Oaxaca MF948699 1
16-09 Sporothrix schenckii Lymphocutaneous Oaxaca MF948700 3
16-020 Sporothrix schenckii Lymphocutaneous Oaxaca MF948701 4
16-021 Sporothrix schenckii Disseminated Oaxaca MF948702 3
16-022 Sporothrix schenckii Lymphocutaneous Oaxaca MF948703 1
16-230 Sporothrix schenckii Lymphocutaneous Mexico City MF948704 1
16-236 Sporothrix schenckii Lymphocutaneous Mexico City MF948705 1
16-237 Sporothrix schenckii Lymphocutaneous Mexico City MF948706 1
16-678 Sporothrix schenckii Lymphocutaneous Jalisco MF948707 1
16-679 Sporothrix schenckii Lymphocutaneous Jalisco MF948708 1
2.1. Phenotypic Characterization
Thirty-nine clinical isolates were re-examined by macroscopic and microscopic studies according
to Marimon criteria [12]. Macroscopic characteristics of colonies were studied by culturing isolates on
potato dextrose agar (PDA); plates were incubated at 30, 35, and 37 ◦C. Petri dishes were inoculated
with colonies of each fungus and 10 µL of conidial suspension adjusted to 1 × 107 cells/mL for each
isolate. After 14 and 21 days, colony diameters were measured in duplicate. Microscopic features of
conidia were determined by slide cultures made on PDA after 12–15 days of incubation in the dark and
in a humid chamber. Coverslips were mounted in lactophenol cotton blue. The slides were examined
under a Nikon Eclipse 50i microscope fitted with a Nikon digital sight DS-2Mv camera. The conidia
were measured. The ability of all isolates to reverse to yeast-like cells at 37 ◦C was performed on brain
heart infusion (BHI) with blood for 9 days. Carbohydrate assimilation was tested using API 20C AUX
strips (bioMerieux, Mexico City, Mexico) [13].
2.2. Antifungal Susceptibility
The antifungal susceptibility test was performed according to the Clinical and Laboratory
Standards Institute (CLSI) M38-A2 broth microdilution method [14]. Briefly, a drug stock solution
was prepared by dissolving an appropriate amount of amphotericin B (AMB; Bristol Myers Squibb,
Princeton, NJ, USA), itraconazole (ITC; Wako Pure Chemicals, Osaka, Japan), voriconazole (VRC, Pfizer,
Inc., New York, NY, USA), posaconazole (PSC; Merck, Rahway, NJ, USA), fluconazole (FLC; Pfizer, Inc,
Amoise, France), terbinafine (TRB; Novartis, Mexico City, Mexico), caspofungin (CSF; Merk, Rahway,
NJ, USA), anidulafungin (ANF; Ben Venve, Northfield Road Bedfor, OH, USA), and micafungin
(MCF; Astellas, Tokyo, Japan). The antifungal concentration ranges were adjusted as follows: 0.125
to 16 µg/mL for AMB, ITC, and VRC; from 0.0313 to 16 µg/mL for PSC; from 0.125 to 64 µg/mL for
FLC; from 0.004 to 2 µg/mL for TRB; and from 0.015 to 8 µg/mL for CFS, ANF, and MCF. The isolates
were cultivated on PDA for 7 days at 30 ◦C; an inoculum was prepared as recommended by the CLSI
and adjusted (80–82% T, λ = 530 nm). The microplates were incubated at 30 ◦C and read at 72 h.
The minimal inhibitory concentration (MIC) endpoint for the triazoles, AMB, MCF, ANF, and TRB was
defined as the lowest concentration that produces complete inhibition of growth; for FLC and CSF,
it was defined as the lowest drug concentration able to inhibit 50% of visible fungal growth. For quality
control of antifungal susceptibilities testing, Candida albicans ATCC 90028, Candida parapsilosis ATCC
22019, and Paecilomyces variotii MYA 3630 were used.
2.3. Molecular Identification
Genomic DNA of isolates was extracted from the mycelial phase of the strain on PDA plates at
30 ◦C for 10 days. DNA was extracted twice with phenol–chloroform and isoamyl–alcohol according
to our previous study [15]. Amplification of the partial calmodulin (CAL) gene was performed using
the degenerated primers sense CL1 5′-GA(GA)T(AT)CAAGGAGGCCTTCTC-3′ and antisense CL2A
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5′-TTTTTGCATCATGAGTTGGAC-3′ [16]. Amplifications were performed in standard condition:
one initial cycle of 3 min at 94 ◦C followed by 30 cycles of 30 s at 94 ◦C, 50 s at 53.4 ◦C, 1 min at 72 ◦C,
and a single extension cycle at 72 ◦C for 5 min. Amplicons were purified using QIAquick (Qiagen,
Hilden, Germany) and sequenced in a Genetic Analyzer 3100 (Applied Biosystems, Foster City, CA,
USA). Sequences were finally edited in Codon code aligner 4.2.7 software and compared in NCBI
GenBank sequences using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) to determine
their identity. Alignments were performed using Clustal Omega software [17]. A phylogenetic tree was
built using the neighbor-joining (NJ) method and a bootstrap analysis [18] of 1000 replicas implemented
in MEGA 6.06 software [19]. The phylogenetic tree was constructed with partial calmodulin gene
sequences encoding calmodulin-encoding gene [18,19]. The analysis of Sporothrix CAL-related
sequences was performed using the sequences obtained in this work (Table 1) and those retrieved from
Genbank—Sporothrix schenckii (KT427643 and KT427645), Sporothrix globosa (KT427636 and KP101459),
Sporothrix brasiliensis (KJ769111), and Sporothrix luriei (KT427639); Sporothrix mexicana (KR269843) was
used as the out-group.
3. Results
3.1. Phenotypic Characterization
A total of 39 clinical isolates from the Microbiology Department collection were studied.
The phenotypic characteristic studied as macroscopic morphologies of all isolates were variable
after 21 days of incubation. The colonies were initially white/cream colored and later turned brown,
then dark brown and with a mixed color on PDA (Figure 1). The colony diameters on PDA after
21 days of incubation attained 30.9± 5.0 mm at 30 ◦C, 11.5± 5.3 mm at 35 ◦C, and 5± 1.8 mm at 37 ◦C.
Microscopic features, conidium size, thermotolerance, dimorphism, and the urease test were performed.
All isolates showed temperature dimorphism and were urease test positive; conidia were hyaline, ovoid,
thick-walled, and almost all isolates were similar. Only three isolates were misidentified as S. globosa
by microscopic features. They exhibited intercalary or terminal conidia formed by sympodial growth
from differentiated conidiophores; the conidia were hyaline to slightly pigmented. Sessile conidia were
sub globosa and dematiaceous (Figure 2). A carbohydrate assimilation test for sucrose and raffinose
was positive for all isolates except one (MF948695), which was negative for raffinose.
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Figure 2. S. globosa morphological characteristics. (A) Hyphae, conidiophore, and sessile conidia
(200×); (B) Sessile conidia (200×); (C) Morphometric analysis (200×); (D) Colony on potato dextrose
agar (PDA) at 30 ◦C in 21 days.
3.2. Antifungal Susceptibility
Antifungal susceptibility testing results are presented in Table 2. Nine drugs were
tested. The antifungal susceptibilities (MIC ranges) were as follows: AMB = 0.5–4 µg/mL,
ITC = 0.125–2 µg/mL, VRC = 0.5–8 µg/mL, PSC = 0.5–8 µg/mL, FLC > 64 µg/mL, TRB = 0.06–1 µg/mL,
CSF = 0.5–8 µg/mL, ANF = 0.25–8 µg/mL, and MCF = 0.5–8 µg/mL. Terbinafine showed the best in vitro
antifungal activity, while fluconazole was ineffective against S. schenckii.
Table 2. The results of MIC50 and MIC90 of nine antifungal drugs against 39 isolates of S. schenckii complex.
Antifungal GM Range (µg/mL) MIC50 (µg/mL) MIC90 (µg/mL)
Amphotericin B AMB 2.554 0.5–4 4 4
Itraconazole ITC 4 0.125–2 4 8
Voriconazole VRC 2.946 0.5–8 2 4
Posaconazole PSC 1.769 0.5–8 1 8
Fluconazole FLC >64 64–>64 64 >64
Terbinafine TRB 0.374 0.06–1 0.5 1
Caspofungin CSF 1.959 0.5–8 2 4
Anidulafungin ANF 2.083 0.25–8 2 4
Micafungin MCF 2.402 0.5–8 2 4
MIC50-MIC90: minimal inhibitory concentration at which 50% and 90% of microorganisms are inhibited.
GM: geometric mea .
3.3. Molecular Identification
olecular identification was done by CAL gen PCR-sequencing. Thirty-eight were identified
as Sporothrix schenckii and one as Sporothrix globosa, which came from the city of General Zaragoza,
Nuevo León and showed a lymphocutaneous clinical presentation. Their geographical origin was as
follows: Mexico City (43.5%), Oaxaca (15.3%), Puebla (10.2%), Nuevo León (7.6%), San Luis Potosí
(7.6%), Veracruz (5.1%), Coahuila (5.1%), and Jalisco (5.1%). The most prevalent clinical presentation
was lymphocutaneous sporotrichosis (92.3%), followed by fixed cutaneous sporotrichosis (5.1%),
and one case of disseminated sporotrichosis (2.5%) (Table 1). Genetic identification was done using a
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fragment of the CAL gene, ~785 base pairs (bp). Our results showed diverse geographic distribution
of clinical isolates in eight states. Thirty-nine isolates were divided into five supported clades. Clade I
consisted of 20 isolates: Mexico City (9), Puebla (3), Oaxaca (3), Jalisco (2), Veracruz (2), and Nuevo
León (1). Clade II consisted of 10 isolates: Mexico City (6), Coahuila (2), Puebla (1), and San Luis Potosi
(1). Clade III consisted of five isolates: Oaxaca (2), Puebla (1), San Luis Potosi (1), Nuevo Leon (1).
Clade IV consisted of three isolates: Mexico City (1), Oaxaca (1), and San Luis Potosi (1). Clade V
consisted of one isolate from Nuevo Leon.
BLAST analysis showed the following identity: Clade (I) KT427643 = MF948670, MF948671,
MF948673, MF948679, MF948680, MF948682, MF948683, MF948689, MF948692, MF948693, MF948694,
MF948697, MF948698, MF948699, MF948703, MF948704, MF948705, MF948706, MF948707,
and MF948708; Clade (II) MF948696 = MF948672, MF948674, MF948676, MF948677, MF948678,
MF948681, MF948684, MF948686, and MF948688; Clade (III) MF948700 = MF948687, MF948690,
MF948691, and MF948702; Clade (IV) MF948701 = MF948675 and MF948685; and Clade (V) MF948695
= KT427636 and KP101459. Thus, there were only five genetic clades according to the CAL gene—I,
II, III, IV, and V. The clade arrangement in a lineage-specific manner is shown in Figure 3. From top
to bottom, S. schenckii, S. brasiliensis, S. globosa, and S. luriei branches can be seen. Finally, S. mexicana
was used as the out-group. Also to note, S. schenckii was subdivided into two subclades: (1) KT427643,
MF948670, and MF948696; and (2) MF948700 and MF948701.
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Figure 3. Phylogenetic tree of the CAL coding sequences from various fungi. The tree was built using
MEGA version 6.06 by the neighbor-joining (NJ) method and further bootstrap analysis of 1000 replicas.
Number on the branches indicate the bootstrap value. From the top to the bottom, clades are in
linage-specific manner. Pink encompasses the clinical species, while blue is the environmental specie
that was used as the out-group. Clinical clade was further divided into small subclades or variants
(ovals) that correspond to the specific Sporothrix specie. Subclades did not match with geographical
origin or antifungal resistance.
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4. Discussion
The species of Sporothrix was previously described as a single species. However, it is now
recognized as S. schenckii complex based on phylogenetic studies using DNA sequence in specific
regions of rDNA, internal transcribed spacer (ITS), calmodulin, β-tubulin, and translation elongation
factor 1 genes. Calmodulin gene in particular has been widely used for taxonomy for Sporothrix
species [5,10]. In our study, 39 isolates were identified by partial sequences of the calmodulin gene.
The phylogenetic tree showed five main branches (variants). These variants matched with Sporothrix
schenckii CAL gene sequences as expected, but their phylogenetic relationship was not related to their
geographical origin. For example, variant 4 had clinical isolates from Mexico City (strain 02-845),
Oaxaca (strain 16-020), and San Luis Potosi (strain 06-743). One isolate (MF948695) was clustered
into the S. globosa clade. In a recent study, S. schenckii sensu stricto was divided in five subclades with
calmodulin for AFLP and phylogenetic analysis of isolates from all over the world [6]. Suzuki et al.,
concluded that Sporothrix species have a distinct virulence profile, but there is no clear relationship
between genotypes S. globosa subgroups I, II, or S. Schenckii sensu stricto and geography in Japan
or clinical forms [5]. The disease is characterized by nodular cutaneous and subcutaneous lesions,
which may involve the adjacent lymphangitic system. The most common clinical manifestation was
lymphocutaneous in this study, which is in agreement with the literature [4,7,11,12,20]. The results
showed that only one isolate was identified as S. globosa. This species was reported in 2006 by
Marimon et al. [12]. S. globosa is the most extensively studied species, with a report on North,
Central and South America, Europe, and Asia [21]. Other reports in our country have revealed
two species that are etiological agents of human sporotrichosis [2,7]. However, S. schenckii sensu
stricto is the most common species that causes sporotrichosis in Mexico [2]. The geographic origin
of Sporothrix species in Mexico is diverse [7]. A recent study of 22 Mexican isolates found San Luis
Potosi as the principal origin. This was contrary to Chakrabarti et al. who reported Puebla as a
high endemic region [2]. We found that most isolates were from Mexico City, followed by Oaxaca.
This does not correspond with the recent report from Rangel-Gamboa et al., which found clinical
isolates from San Luis Potosi, followed by Puebla. However, the most frequent clinical manifestation
was lymphocutaneous, which conformed to our finding. The distribution of S. globosa has been
reported in many countries [4–6,8,13,21,22]. A few reports of clinical presentations of this species exist;
most presentations were lymphocutaneous, with fixed cutaneous being a less frequent disseminated
presentation [4,8,22]. In this work, lymphocutaneous was the most frequent presentation. Our clinical
isolate identified as S. globosa (MF948695) had a lymphocutaneous sporotrichosis. This isolate grew well
at both 30 ◦C and 35 ◦C and the growth was restricted at 37 ◦C; this was the same results reported by
Camacho et al. [22]. Treatment for sporotrichosis depends on the clinical manifestation; intolerance to
iodine and the high toxicity of amphotericin B limits its use. In the last decades, azole derivatives have
been the most effective drugs [23]. Antifungal susceptibility testing varies substantially in reports
of in vitro susceptibility from human clinical isolates. We documented susceptibility of the in vitro
profile of Sporothrix schenckii complex with molecular identification from China, Japan, Iran, Brazil,
and Argentina [5,9,21,22,24,25]. In the present study, we evaluated nine antifungal agents against
the mycelial phase of S. schenckii complex and showed that terbinafine was the most effective drug
with a low MIC, while fluconazole was less active; this was comparable to other studies [9,25–27].
Recently Cordoba et al. described similar results for S. schenckii and S. globosa in mycelial phase in
Argentina [25]. The behavior of S. globosa was equal to other isolates in this study.
5. Conclusions
The major species involved in human sporotrichosis are S. schenckii, S. brasiliensis, and S. globosa
of diverse geographic origin. Sporotrichosis is common in regions of Latin America with tropical
climates. In Mexico, it is a relevant mycosis, mainly in farmers who work with a variety of
vegetation [7]. S. schenckii has revealed a high genetic diversity and a recent population expansion
process, while S. globosa and S. brasiliensis has shown a rapid clonal distribution [8]. The isolates
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studied in this paper revealed a high degree of genotypic variability among S. schenckii sensu stricto
isolates. Based on geographic origin, S. schenckii complex have a wide geographical distribution in our
country. Our study showed there was no significant difference in the antifungal in vitro susceptibility
among Sporothrix species, including S. globosa in filamentous phase. This study of S. globosa represents
the first report of a clinical isolate from Northern Mexico.
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